LSI USA '25 Almost at Capacity: Register Today arrow-icon
Feb 14, 2025

The Weekly Recap 2/14/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

The Weekly Recap 2/14/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

Weekly Recap 16_9 - 02.14.2025

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni obtain regulatory approvals, secure over $41M in new funds, form new partnerships, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).

1MED

Appointed David Bird as its new Chief Commercial Officer and John Thomas as its new Director of Strategic Delivery. 1MED is a provider of solutions tailored to the medtech industry, delivering global expertise in the development of medical devices, novel technologies, and combination products.

Accelus

Announced that its FlareHawk Interbody Fusion System was granted regulatory approval in Brazil by the Brazilian Health Regulatory Agency (ANVISA). FlareHawk is an expandable spinal implant designed to expand in width, height, and lordosis via the company’s proprietary Adaptive Geometry technology.

CorVista Health

Appointed Adrian Lam as President and CEO, succeeding Don Crawford, as he retires from his 42-year career in medtech. Additionally, Tim Attebery—CEO of Cardiovascular Associates of America, former CEO of the American College of Cardiology (ACC), and current Board Director—was appointed Board Chairman.

Exero Medical

Closed a $12.7M preferred seed financing. The new funds will support the completion of its FDA pivotal trial and the launch of its xBar system—an FDA breakthrough-designated post-operative tissue healing monitoring solution—in the United States.

IBEX Medical Analytics

Announced that its Ibex Prostate received FDA 510(k) clearance. Ibex Prostate is a software-only device that analyzes scanned histopathology whole slide images (WSIs) and is designed to assist pathologists in improving prostate cancer detection and grading.

ImpediMed

Announced a five-year $15M growth capital facility with SWK Holdings to support commercialization activities and growth. ImpediMed is the developer of the SOZO Digital Health Platform, the only FDA-cleared bioimpedance spectroscopy (BIS) solution for clinically assessing breast cancer-related lymphedema.

Lymphatica Medtech

Announced the publication of its latest research: "Advancing women's health with a pioneering implant to treat breast cancer-related lymphedema." The company’s product, LymphoDrain, is a permanent implant designed to recirculate lymph inside the body to restore physiological fluid equilibrium.

Newronika

Successfully closed a  €13.6M Series B funding round led by a new investor, Fondazione ENEA Tech e Biomedical. The funds will support the clinical validation and commercialization of its adaptive deep brain stimulation (aDBS) platform.

Nina Capital

Reached the first close of its third fund of €50M. The company plans to utilize the funds to invest in 25 early-stage healthtech founders, with 60% based in Europe and the remaining based in the United States, Canada, Israel, and Australia.

OstomySecure

Announced a partnership with AIG Hospital in the trial phase of its Transcutaneous Implant Evacuation System (TIES) IV. TIES is a transcutaneous implant solution designed to improve the quality of life for ostomy patients by providing a non-bag-based method for waste evacuation.

Paradromics

Announced a strategic investment from NEOM, a large Saudi Arabia-based project intended to be a hub for technological innovation and sustainable living. The partnership aims to accelerate the development of BCI-based healthcare in the MENA region.

Vitazi.ai

Announced a partnership with Eye Associates of New Mexico to enhance AI-powered retinal screening. The collaboration will support retinal diagnostics and early disease detection using advanced AI diagnostics.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.